Digital Neuro Biomarkers Market Size, Share and Trends Analysis, By Biomarker Type (Physiological Biomarkers, Behavioral Biomarkers, Digital Imaging Biomarkers, and Smart Device–Derived Biomarkers), By Technology, By Application, By End-Use, and By Region, Forecast 2025-2032

Digital Neuro Biomarkers Market Overview and Key Insights:

The digital neuro biomarkers market size reached USD 688.7 million in 2024 and is expected to register a revenue CAGR of 26.3% during the forecast period. Digital cognitive biomarkers have been utilized in medication development for several years to track drug activity in the central nervous system. These biomarkers, which serve as objective, repeatable, and reliable indicators of cognitive performance, can include measures such as attention, memory, processing speed, and executive function, and are obtained through a variety of digital-based tasks such as reaction time tests, working memory, and visual searches.

Market Drivers:

Rising prevalence of neurological disorders is a key driver of revenue growth in the digital neuro biomarkers market. According to the Alzheimer’s Organization, alzheimer’s is the leading cause of dementia, accounting for approximately 60% to 80% of cases. Approximately 5% to 10% of dementia patients exhibit vascular dementia alone. Alzheimer’s disease affects more than 7 million Americans. By 2050, this figure is expected to increase to approximately 13 million. Alzheimer’s dementia can also affect people under the age of 65. Although prevalence studies on younger-onset dementia in the US are sparse, experts estimate that approximately 110 out of every 100,000 people aged 30 to 64 have the condition, totalling over 200,000 Americans.

Growing demand for remote monitoring and telehealth is another key driver driving the market revenue growth. Digital biomarkers enable monitoring outside of traditional health care settings, lowering barriers to involvement in research or clinical care such as trip costs, distance, effort, logistics, infectious exposure, time, and transportation. As large-language models have transformed natural language processing in AI, multimodal models will integrate digital sensor, laboratory, imaging, electrodiagnostic, and clinical data to improve health care decision-making, efficiency, and care delivery.

On November 2024, DANNCE.AI raised USD 2.6 million in pre-seed funding led by LDV Capital, following initial investment from Glasswing Ventures, with participation from The Leo Lion Company, Duke Capital Partners, and Merck Digital Sciences Studio. DANNCE is a new approach to the clinical exam that ingests videos of patients and automatically analyzes them for evidence of neurological disease. The platform can also evaluate the efficacy of drugs for patients with neurological disorders.

Market Opportunity:

Emergence of personalized neurology and predictive medicine and integration of Artificial Intelligence (AI) and machine learning acts as opportunities for digital neuro biomarkers market. The integration of AI, machine learning, and digital biomarkers has the potential to revolutionize the field of clinical research by providing optimized disease diagnosis and treatment strategies. AI and ML algorithms can identify patterns in large data sets, discover novel biomarkers, and improve accuracy in existing biomarkers. Digital biomarkers, leveraging the widespread adoption of digital health technologies, offer objective and quantifiable data for healthcare assessment.

In August 2023, the European Medicines Agency formally qualified the first DHT-derived digital primary endpoint, a novel stride-velocity measure, for drug development in Duchenne Muscular Dystrophy as a substitute to traditional walking tests. The advantages of digital endpoint continuous monitoring over long periods of time, reduced reliance on patient motivation, and other factors raise the possibility of approval beyond the limits of the 6-minute walk test.

Recent Trends:

Emerging trends include Artificial Intelligence (AI) and Machine Learning (ML) for biomarker discovery, wearable and mobile sensor integration, digital phenotyping, and Augmented and Virtual Reality (AR/VR) for neuro assessment.

New biomarkers derived from artificial intelligence show great promise, including those that can use voice, facial expression, or changes in social contact from personal devices to detect early signs of diagnosis or relapse. Cognitive biomarkers have grown in popularity in psychiatry and neurology due to their capacity to link to both functional relevance and biological basis. In early-stage therapeutic research, cognition provides a technique of translating target engagement from preclinical to human trials, detecting early indicators of brain safety and/or efficacy, and so aiding decision-making. In later stages, digital cognitive assessments are commonly used as endpoints in CNS trials, as well as in childhood or late-life diseases where determining long-term brain safety is critical for regulatory approval.

On April 2024, Tata Power Community Development Trust (TPCDT) has teamed with Tata Elxsi, a global leader in design and technology services, to further the “Pay Autention” project. Using Tata Elxsi’s innovative digital therapeutics (DTx) solution, TEcare, TPCDT hopes to accelerate the development of the India Neurodiversity Platform. This phygital platform is the result of a collaboration between Tata Power Community Development Trust (TPCDT) and the National Institute for the Empowerment of Persons with Intellectual Disabilities (NIEPID), and it is intended to help people with neurodiversity issues, particularly children with autism. It will significantly improve neurodiversity screening, diagnosis, disease management, and care for people with special needs.

Restraints & Challenges:

Despite the potential benefits of digital biomarkers, their application in clinical development and practice poses challenges. One of the most significant issues is assuring the validity and reliability of digital biomarkers, which necessitates extensive validation studies and measurement technique standardization. This is especially crucial given the diverse variety of digital biomarkers being developed, as well as the possibility of diversity in data collecting across different devices and platforms.

Other ethical concerns include equity in health care access, structural biases in database building and validation, data ownership, and responsibility in health care decision-making. The approval process for DBs differs by country and can be extensive. For example, in the United States, the BQP22 aims to process applications from submission to decision within 19 months. Changes to biomarkers or context of use necessitate re-engaging the BQP. Without adjustments in regulatory processes, timelines would struggle to keep up with the rapid advancement of database technologies.

Biomarker Type Segment Insights and Analysis:

Based on the biomarker type, the digital neuro biomarkers market is segmented into physiological biomarkers, behavioral biomarkers, digital imaging biomarkers, and smart device–derived biomarkers.

Smart device–derived biomarkers segment contributed the highest growth rate during the forecasted period. A digital biomarker related to IoT relies on objectivity. Unlike traditional evaluation methods, which healthcare providers test only during hospital visits, digital biomarkers measure patients’ health in real-world settings, including at home, and provide precise insights into their health and performance. Researchers continuously test digital biomarkers to collect large amounts of data from individual patients. Because of these advantages, developers use them in medical IoT applications, such as real-time monitoring of Parkinson’s or Alzheimer’s disease. Additionally, researchers can evaluate the effects of a novel treatment more objectively in fewer people using digital biomarkers compared to traditional clinical trials.

On June 2025, Empatica, a pioneer in digital biomarker research and patient monitoring with wearables and artificial intelligence, has revealed the EmbraceMini, a groundbreaking new clinical trial gadget. It wirelessly transmits sensor data to the FDA-cleared Empatica Health Monitoring Platform, allowing for continuous analysis and extraction of precise digital biomarkers from clinical trial participants while increasing compliance. EmbraceMini can track digital biomarkers related to physical activity, sleep, gait, and light exposure, which can be used as digital endpoints in studies investigating sleep disorders, movement disorders, obesity, depression, pain, and other conditions.

Technology Segment Insights and Analysis:

Based on the technology, the digital neuro biomarkers market is segmented into Artificial Intelligence & machine learning, digital twins/simulations, Natural Language Processing (NLP), neuroimaging integration platforms, and others.

Neuroimaging integration platforms segment contributed the largest market share in 2024. Imaging-based biomarkers (IBB) are invaluable in neurology, providing critical insights into the structural, functional, and molecular changes associated with neurological diseases. Digital biomarkers for fatigue monitoring in neurological disorders are a novel approach to closing the gap between mechanistic understanding and clinical application. These digital biomarkers can be evaluated using a multimodal approach that includes neuroimaging markers, clinical assessments, performance metrics, and patient-reported outcomes.

Emerging Digital Phenotyping (DP) technologies allow for brain activity monitoring, which provides valuable insights into cognitive functions, emotional states, and neurological conditions. Researchers hope to create full neurological profiles by combining brain activity data with other digital biomarkers. These profiles will inform targeted interventions and therapies for illnesses such as depression, anxiety, and neurodegenerative disorders.

On March 2024, Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced that Merck, also known as MSD outside of the United States and Canada, has joined its Data Syndication Partnership program for the LEARNS observational study, which aims to develop digital biomarkers in neurodegenerative disorders using smart phone-based assessments and wearable technologies.

Application Segment Insights and Analysis:

Based on the application, the digital neuro biomarkers market is segmented into neurodegenerative disorders, psychiatric & mood disorders, neurodevelopmental disorders, sleep disorders, and clinical trials and drug development.

Neurodegenerative disorders segment contributed the largest market share in 2024. The most prevalent neurodegenerative disorders are alzheimer’s disease, parkinson’s disease, prion disease, amyotrophic lateral sclerosis, motor neuron disease, huntington’s disease, spinal muscular atrophy, and spinocerebellar ataxia. According to the Parkinson Organization, in the United States, an estimated 1.1 million people live with Parkinson’s disease (PD). By 2030, experts predict that this figure will rise to 1.2 million. Parkinson’s ranks as the second most common neurological illness after Alzheimer’s. Each year, doctors diagnose approximately 90,000 people in the United States with Parkinson’s disease. An estimated ten million people around the world currently live with Parkinson’s disease.

On July 2025, IXICO, a global leader in neuroscience imaging and biomarker analytics that uses its AI-powered platform to help advance drug development in neurological disorders, announced that it has expanded its existing collaboration with the Global Alzheimer’s Platform Foundation (GAP) by signing an agreement securing full data usage rights in GAP’s landmark Bio-Hermes-002 study.  According to the terms of the deal, IXICO will pay GAP in cash and analysis services in exchange for data usage rights.

Geographical Outlook:

Digital neuro biomarkers market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Digital Neuro Biomarkers Market:

North America is registered to have highest market share in digital neuro biomarkers market in 2024. This is mainly driven by rising prevalence of neurological disorders, growing demand for remote monitoring and telehealth, and increased use of biomarkers in clinical trials. According to the National MS Society, Multiple sclerosis (MS) is one of the most common debilitating neurological disorders affecting young adults around the world. It affects nearly one million people in the United States and an estimated 2.9 million people worldwide. Every week, approximately 200 new cases are diagnosed in the United States.

On January 2025, Neurogen Biomarking and Linus Health, a digital health startup dedicated to altering people’s brain health throughout the world, has reached an agreement to integrate Linus Health’s scientifically proven digital cognitive tests into the Neurogen Biomarking ecosystem. The ecosystem incorporates Linus Health’s advanced digital cognitive assessments, which identify high-risk individuals and determine their suitability for further evaluation.

Asia Pacific Digital Neuro Biomarkers Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period, driven by growing demand for remote monitoring and telehealth, increased use of biomarkers in clinical trials, and advancements in wearables and mobile technologies. The use of digital health technologies is rapidly expanding in the Asia-Pacific (APAC) region. Wearables, such as fitness trackers and smartwatches, serve an important role in continually monitoring physiological indicators like heart rate, sleep patterns, and activity level. Mobile applications for medication adherence, chronic disease management, and mental health assistance are rapidly growing. These apps collect data on medicine use, symptom tracking, and user behavior to provide a comprehensive picture of real-world treatment effectiveness and adherence trends in varied groups.

On January 2022, GrayMatters Health (GMH), the developer of digital self-neuromodulation treatments for mental diseases, has announced the successful completion of its USD 10 million Series A funding round. Otsuka Medical Devices Co., Ltd. (OMD) was the primary investor in this round. In addition to its investment, OMD acquired some rights to Prism in Japan and other Asian markets. Joy Ventures, J-Ventures, and J-Impact participated in the Series A round as well.

Europe Digital Neuro Biomarkers Market:

Europe is expected to have considerable market share in 2024. The integration of AI and machine learning into digital tools significantly improves their predictive precision and analytical performance. In Europe, the market is being propelled by favorable regulatory policies, growing investments in healthcare technologies, and strategic partnerships between technology firms and healthcare organizations.

On December 2024, Neuroelectrics, a pioneer in high-definition brain stimulation and EEG technology, has collaborated with Neuronostics, an innovator in advanced digital biomarkers and EEG analysis, to provide an integrated EEG solution tailored to pharmaceutical, contract research organizations (CROs), and academic partners. This collaboration combines Neuroelectrics’ cutting-edge EEG gear with Neuronostics’ patented analytics to accelerate clinical trials and open up new avenues for neurological research.

Competition Analysis:

The digital neuro biomarkers market is characterized by a fragmented structure, with several players competing across various segments and regions. list of major players included in the digital neuro biomarkers market report are:

• NeuraMetrix, Inc.
• Verily
• Koneksa Health
• Altoida
• Linus Health
• Neurotrack Technologies, Inc.
• BioSensics
• Viewmind
• Brainomix
• Neuronostics Ltd
• Bottneuro AG
• Indivi AG
• Navify (F. Hoffmann-La Roche Ltd.)
• IXICO plc
• Clinical ink

Strategic Developments in Digital Neuro Biomarkers Market:

• In April 2025, Clinical ink, a global pioneer in life science technology, announced the release of TrialLens, a fully integrated, AI-powered analytics dashboard that changes the way clinical trial eCOA data is visualized, searched, and analyzed. TrialLens provides real-time, actionable insights into study operations, participant behavior, and digital biomarker measures for both decentralized and hybrid clinical trials. TrialLens, built on a modern data architecture, integrates the power of Snowflake’s data cloud with Amazon Web Services (AWS) technologies such as Bedrock, Q, and QuickSight to enable easy access to dynamic trial insights.
• In April 2024, Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction, and neurological disorders, has signed a licensing agreement with Braingaze Ltd. (Braingaze) and launched its new business, Tris Digital Health, which will develop and commercialise digital diagnostic and therapeutic products for neurological health conditions.
• In March 2024, Indivi, a major MedTech firm based in Basel, Switzerland, has signed an agreement with Biogen to expand digital health technologies and create digital biomarkers for Parkinson’s disease. As part of the arrangement, Biogen will license Konectom to Indivi, a smartphone-based digital biomarker platform that examines brain processes remotely for more precise, frequent disease progression measurements.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of The Digital Neuro Biomarkers Market Report:

The Digital Neuro Biomarkers market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Biomarker Type Outlook (Revenue, USD Million; 2022-2032)
  • Physiological Biomarkers
  • Behavioral Biomarkers
  • Digital Imaging Biomarkers
  • Smart Device–Derived Biomarkers
    • Smartphone Usage Patterns
    • Wearable
    • GPS and Location Tracking
    • Others

• Technology Outlook (Revenue, USD Million; 2022-2032)
  • Artificial Intelligence & Machine Learning
  • Digital Twins / Simulations
  • Natural Language Processing (NLP)
  • Neuroimaging Integration Platforms
  • Others

• Application Outlook (Revenue, USD Million; 2022-2032)
  • Neurodegenerative Disorders
  • Psychiatric & Mood Disorders
  • Neurodevelopmental Disorders
  • Sleep Disorders
  • Clinical Trials and Drug Development

• End-Use Outlook (Revenue, USD Million; 2022-2032)
  • Hospitals and Clinics
  • Pharmaceutical and Biotechnology Companies
  • Research Institutes and Academic Centers
  • Contract Research Organizations (CROs)
  • Home Healthcare Providers

• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the Digital Neuro Biomarkers market report